NCT00646503View on ClinicalTrials.gov

Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Telbivudine

600 mg/day, oral telbivudine for 52 weeks

Trial Locations (1)

Unknown

Novartis Investigative Site, Beijing

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY